Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed · Phase 1/Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines made from white blood cells treated with antigens may make the body build an immune response to kill melanoma cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may kill more melanoma cells. PURPOSE: This phase I/II trial is studying the side effects and how well giving vaccine therapy and interleukin-2 works compared to vaccine therapy alone in treating patients with metastatic melanoma that has not responded to previous therapy.

Key facts

Study ID

NCT00019214

Run by

National Cancer Institute (NCI)

Starts

1997-04-01

Expected to finish

2006-07-01

Last updated by the study team

2013-06-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.